Detailed Information on Publication Record
2015
Various forms of F-18-FDG PET and PET/CT findings in patients with polymyalgia rheumatica
ŘEHÁK, Zdeněk, Jiří VAŠINA, Petr NĚMEC, Zdeněk FOJTÍK, Renata KOUKALOVÁ et. al.Basic information
Original name
Various forms of F-18-FDG PET and PET/CT findings in patients with polymyalgia rheumatica
Authors
ŘEHÁK, Zdeněk (203 Czech Republic, guarantor, belonging to the institution), Jiří VAŠINA (203 Czech Republic, belonging to the institution), Petr NĚMEC (203 Czech Republic, belonging to the institution), Zdeněk FOJTÍK (203 Czech Republic, belonging to the institution), Renata KOUKALOVÁ (203 Czech Republic), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Dorota REHAKOVA (203 Czech Republic), Jan ADAM (203 Czech Republic), Alena VAVRUSOVA (203 Czech Republic) and Zdeněk ADAM (203 Czech Republic, belonging to the institution)
Edition
Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Palacký University, 2015, 1213-8118
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30000 3. Medical and Health Sciences
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 0.924
RIV identification code
RIV/00216224:14110/15:00083435
Organization unit
Faculty of Medicine
UT WoS
000366566700018
Keywords in English
FDG; PET; PET/CT; polymyalgia rheumatica; bursitis; vasculitis; synovitis; giant cell arteritis
Tags
Tags
International impact, Reviewed
Změněno: 29/11/2016 15:00, Soňa Böhmová
Abstract
V originále
PMR presents by articular/periarticular synovitis, extraarticular synovitis and can be accompanied by giant cell arteritis. All types of involvement have their distinct FDG PET (PET/CT) finding, which can be seen either individually or in any of their 4 combinations. FDG PET (PET/CT) examination seems to be an advantageous one-step examination for detecting different variants of PMR, for assessing extent and severity and also for excluding occult malignancy.